Provectus Biopharmaceuticals (PVCT) Stock Overview
A clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PVCT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Provectus Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.065 |
| 52 Week High | US$0.10 |
| 52 Week Low | US$0.038 |
| Beta | 0.80 |
| 1 Month Change | 18.40% |
| 3 Month Change | 44.44% |
| 1 Year Change | -25.49% |
| 3 Year Change | -51.45% |
| 5 Year Change | -11.68% |
| Change since IPO | -94.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| PVCT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.0% | 5.0% | 1.1% |
| 1Y | -25.5% | 44.3% | 28.7% |
Return vs Industry: PVCT underperformed the US Pharmaceuticals industry which returned 44.2% over the past year.
Return vs Market: PVCT underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| PVCT volatility | |
|---|---|
| PVCT Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PVCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PVCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 6 | Ed Pershing | www.provectusbio.com |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company’s lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Provectus Biopharmaceuticals, Inc. Fundamentals Summary
| PVCT fundamental statistics | |
|---|---|
| Market cap | US$27.32m |
| Earnings (TTM) | -US$5.58m |
| Revenue (TTM) | US$57.48k |
Is PVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PVCT income statement (TTM) | |
|---|---|
| Revenue | US$57.48k |
| Cost of Revenue | US$1.74m |
| Gross Profit | -US$1.68m |
| Other Expenses | US$3.90m |
| Earnings | -US$5.58m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | -2,930.58% |
| Net Profit Margin | -9,709.81% |
| Debt/Equity Ratio | -39.4% |
How did PVCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 05:12 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Provectus Biopharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Vendetti | Maxim Group |
| I-Eh Jen | Maxim Group |
| Ricky Snyder | Maxim Group |